Best Clinical Genomics Companies in California, United States

Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.

Funding rounds

• Nov 2025Post IPO$350M
• Nov 2020Post IPO$1B
• Aug 2017Series E$360M
• Jan 2016Series D$100M

Founders & team

Amirali TalasazCo-founder and Co-Chief Executive OfficerRoberto MignoneBoard of DirectorsHelmy EltoukhyChairman and Co-Chief Executive Officer

Investors

Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group

Tech stack

Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd

Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.

Funding rounds

• Apr 2026Series A$5M
• Jun 2025Series A$25.4M
• Jul 2023Series A$48.5M
• Jun 2021Series A$60M

Founders & team

Manish AgarwalCo-FounderScott BratmanCo-Founder

Investors

F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp

Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.

Funding rounds

• May 2025Series C$21.8M
• May 2021Series C$70M

Founders & team

Dave MullarkeyChief Executive Officer

Investors

Pathology Asia Holdings

Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.

Funding rounds

• Jan 2026Series C$50M
• Feb 2024Series C$100M
• Sep 2021Series B$80M
• Jul 2020Grant (prize money)$321.9K

Founders & team

Steve ChenCo-FounderYuling LuoCo-Founder & CEO

Investors

Sands Capital, Sherpa Healthcare Partners, Morningside, Samsara BioCapital, Qiming Venture Partners, Illumina Ventures

Tech stack

Apple Icloud MailBootstrapCloudflareCloudflare Bot ManagementCookieyesCore-Js

Developer of rapid antimicrobial susceptibility testing devices for life sciences. The company provides LifeScale, a rapid antimicrobial susceptibility testing technology that offers population-profiling for Gram-negative bacteria in positive blood culture. It also offers primary and secondary antibodies, peptides, reagent kits, inhibitors, and other related products.

Funding rounds

• Mar 2026Post IPO$2.3M
• Nov 2024Series B$14.4M
• Jun 2024Series A$3.7M
• Nov 2023Series A$2.4M

Founders & team

Ken BabcockCEO

Investors

National Science Foundation

Developer of small-molecule drugs for the treatment of cancer. The company utilizes its proprietary Chemoproteomics platform, IMTAC that enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.

Funding rounds

• Oct 2025Series B$28M
• Jul 2022Series B$38.5M
• May 2021Series A$12M
• Sep 2020Grant (prize money)$298.9K

Founders & team

Irene YuanCo-Founder & Executive Vice PresidentPing CaoCo-Founder & CEO

Investors

Kaitai Capital Management, Lapam Capital, Deyi Capital, Junson Capital, HHS, Bayland Capital

Developer of diagnostic assays using RNA sequencing. The company's product includes ImmunoPrism is an RNA sequencing-based assay that uses predictive immune modeling to generate multidimensional biomarkers. It combines machine learning and RNA-sequencing to build gene expression models for immune cells. The company's models for key immune cells include Immune Health Expression Models, Immune Escape Genes, and Co-inhibitory molecules. The company's sequencing products include mRNAble, Total RNAble, picoRNA, FFPExact, miRNAble, RNAccess, RNAmplify, and RNAdvantage.

Funding rounds

• Dec 2025Series A—
• Aug 2023Series A$1.2M
• Dec 2021Series A$6.9M
• Jun 2017Series A$18M

Founders & team

Jarret GlasscockChief Executive Officer

Investors

7percent Ventures, Menlo Ventures, DCVC, Ascension Ventures, Y Combinator, iSelect Fund

Tech stack

AccessibeAmazon S3Amazon Web ServicesApple Icloud MailCloudflareContact Form 7

Provider of non-invasive diagnostic tests for pregnant women. The company offers blood test-based diagnostics to predict the fetal development and health conditions of prenatal babies. They perform the detection of nine cell-free RNA (cfRNA) which help in measuring the gestational age of the fetal. The other non-invasive tests in which the maternal blood is analyzed for the cRNA to detect the preterm risk management solutions(advance of labor) in women.

Funding rounds

• Jul 2025Series B$23.7M
• Aug 2023Grant (prize money)$4.6M
• May 2022Conventional Debt—
• May 2022Series B$60M

Founders & team

Mads MelbyeCo-FounderManeesh JainCo-Founder & CEOManfred LeeChief Operating Officer

Investors

Comerica, Decheng Capital, BlackRock, Foresite Capital, General Catalyst, Google Ventures

Provider of food safety technologies for the identification of pathogens. The company offers Clear Dx, a rapid, high throughput next-generation sequencing (NGS) platform for clinical and public health labs that offers a complete characterization of SARS-CoV-2.

Funding rounds

• Dec 2024Series D$30M
• May 2021Series C$60M
• May 2020Series B$39.5M
• Apr 2019Series B—

Founders & team

Sasan AminiCo-Founder & CEO

Investors

Google Ventures, Menlo Ventures, Khosla Ventures, Redmile Group, Wing Venture Capital, Dentsu

Tech stack

Apple Icloud MailGodaddyGoogle AnalyticsGoogle Tag ManagerGoogle WorkspaceJquery

Digital molecular biology analytics for disease management The proprietary platform is designed to be used in conjunction with existing qPCR instruments and to increase their multiplexing capabilities. Using their proprietary cloud-based software and assay design.

Provider of diagnostic solutions for systemic infections. Its proprietary technology, based on research from Stanford University, measures gene expression patterns related to the immune system to diagnose sepsis. It provides products such as InSep for acute infection and sepsis tests, ViraBac for acute infection tests, SARC-CoV-2 swabs, etc.

Funding rounds

• Sep 2024Series E$57M
• Jul 2023Grant (prize money)$299.8K
• Nov 2021Grant (prize money)$12.1M
• Nov 2021Grant (prize money)$1.7M

Founders & team

Jonathan RomanowskyCo-Founder and Chief Business Officer

Investors

GSVP, Khosla Ventures, Think.Health, Northpond Ventures, StartX, DARPA

Tech stack

BootstrapBricksCloudflareCloudflare Bot ManagementContact Form 7Core-Js

Provider of clinical and DTC genomic testing services. The company offers genomic testing services to consumers and healthcare providers in the areas of reproductive genetics, cancer genetics, cardiovascular diseases, and pediatrics as well as direct to consumer tests for assessment of the risk of various medical conditions.